StockData
Upstream Bio, Inc. logo

Upstream Bio, Inc. (UPB) stock

UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 9/30
$3.41+0.14 (+4.28%)

Close on Oct 30, 2026Market cap $186.77MP/E –Yield –

Earnings

Upstream Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$773.00K
-17.5% on a year earlier
EPS, Q2 FY2026
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Upstream Bio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 4, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open$773.00K-17.5%–Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open$1.03M+82.7%–Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026before the open$668.00K+9.0%–Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025before the open$683.00K+12.5%–Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025before the open$937.00K––Release
Q1 FY2025ended Mar 31, 2025May 6, 2025before the open$566.00K––Release
Q4 FY2024ended Dec 31, 2024Mar 12, 2025before the open$613.00K––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$607.00K––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Upstream Bio has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Upstream Bio puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Upstream Bio filed with the SEC as exhibits to Form 8-K or 6-K

  1. Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
    Update
  2. Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
    Results
  3. Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
    Results
  4. Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
    Results
  5. Top-line Results for the Phase 2
    Results
  6. Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the
    Update
  7. Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
    Results
  8. Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    Update
  9. 8-K exhibit EX-99.2
    Update
  10. Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
    Results
  11. Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
    Results
  12. Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
    Results
  13. Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
    Results